SCHEMBL516463

SCHEMBL516463

CCn1cnc2c1c(=O)[nH]c(=O)n2CC

nearest known ligand 0.81

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 6/20 0.81
ADORA2A P29274 6/20 0.81
PDE4B Q07343 6/20 0.81
PDE4C Q08493 6/20 0.81
PDE4D Q08499 6/20 0.81
BRD4 O60885 9/20 0.76
BRD2 P25440 2/20 0.76
BRD3 Q15059 2/20 0.76
BRDT Q58F21 2/20 0.76
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
ALDH1A1 P00352 1/20 0.65
ADORA2B P29275 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21381257 0.89 PDE4A (1.00) PDE4AADORA2APDE4BPDE4CPDE4D
SCHEMBL7464482 0.89 PDE4A (0.86) PDE4AADORA2APDE4BPDE4CPDE4D
SCHEMBL19066317 0.87 BRD4 (1.00) PDE4AADORA2APDE4BPDE4CPDE4D
SCHEMBL7031729 0.87 MEN1 (0.87) PDE4AADORA2APDE4BPDE4CPDE4D
SCHEMBL7454403 0.86 PDE4A (0.61) PDE4AADORA2APDE4BPDE4CPDE4D
SCHEMBL9055277 0.86 PDE4A (0.61) PDE4AADORA2APDE4BPDE4CPDE4D
SCHEMBL554932 0.84 BRD4 (0.81) PDE4AADORA2APDE4BPDE4CPDE4D
SCHEMBL9565477 0.84 PDE4A (0.65) PDE4AADORA2APDE4BPDE4CPDE4D
SCHEMBL19090444 0.84 BRD4 (1.00) PDE4AADORA2APDE4BPDE4CPDE4D
SCHEMBL12257284 0.84 PDE4A (0.80) PDE4AADORA2APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250386846-A1 Food Compositions Including Aragonite NANT HOLDINGS IP LLC (US) 2025-12-25 US disclosed
US-12419336-B2 Beverage compositions including calcium supplied from aragonite and methods of making the same NANT HOLDINGS IP, LLC (US) 2025-09-23 US disclosed
US-20250194654-A1 Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same NANT HOLDINGS IP, LLC 2025-06-19 US disclosed
US-12310392-B2 Beverage compositions including calcium supplied from aragonite and methods of making the same NANT HOLDINGS IP, LLC (US) 2025-05-27 US disclosed
US-20240381918-A1 Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same NANT HOLDINGS IP, LLC 2024-11-21 US disclosed
US-12089621-B2 Beverage compositions including calcium supplied from aragonite and methods of making the same NANT HOLDINGS IP, LLC (US) 2024-09-17 US disclosed
US-20230354865-A1 Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same NANT HOLDINGS IP, LLC 2023-11-09 US disclosed
US-11793224-B2 Beverage compositions including calcium supplied from aragonite and methods of making the same NANT HOLDINGS IP, LLC (US) 2023-10-24 US disclosed
US-20230085907-A1 Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same NANT HOLDINGS IP, LLC 2023-03-23 US disclosed
US-11533940-B2 Beverage compositions including calcium supplied from aragonite and methods of making the same NANT HOLDINGS IP, LLC (US) 2022-12-27 US disclosed
WO-2001093833-A2 KITS AND METHODS FOR OPTIMIZING THE EFFICACY OF CHONDROPROTECTIVE COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2001-12-13 WO disclosed
WO-2001093832-A2 AQUEOUS CHONDROPROTECTIVE COMPOSITIONS HAVING DEFINED DOSAGE REQUIREMENTS FOR EFFICACIOUS DELIVERY THE PROCTER & GAMBLE COMPANY (US) 2001-12-13 WO disclosed
WO-2001005253-A1 COMPOSITIONS, KITS, AND METHODS FOR PROVIDING AND MAINTAINING ENERGY AND MENTAL ALERTNESS THE PROCTER & GAMBLE COMPANY (US) 2001-01-25 WO disclosed
EP-0413278-B1 Use of xanthine derivatives against peptic ulcers HOECHST JAPAN (JP) 1996-11-06 EP disclosed
US-5109003-A METHOD FOR THE TREATMENT OF PEPTIC ULCER DISEASE HOECHST JAPAN LIMITED (JP) 1992-04-28 US disclosed
EP-0413278-A2 Use of xanthine derivatives against peptic ulcers HOECHST JAPAN LIMITED (JP) 1991-02-20 EP disclosed
US-4713455-A FOR OBSTRUCTIVE DISORDERS OF THE RESPIRATORY TRACT HOECHST AKTIENGESELLSCHAFT (DE) 1987-12-15 US disclosed
US-4616020-A TREATING OBSTRUCTIVE RESPIRATORY DISEASES HOECHST AKTIENGESELLSCHAFT (DE) 1986-10-07 US disclosed
EP-0075850-B1 PHARMACEUTICAL PREPARATIONS CONTAINING VICINAL DIHYDROXYALKYL XANTHINES, PROCESS FOR THE PREPARATION OF THE XANTHINES AND THE APPROPRIATE INTERMEDIATES THEREFOR HOECHST AKTIENGESELLSCHAFT (DE) 1985-12-18 EP disclosed
EP-0075850-A2 Pharmaceutical preparations containing vicinal dihydroxyalkyl xanthines, process for the preparation of the xanthines and the appropriate intermediates therefor HOECHST AKTIENGESELLSCHAFT (DE) 1983-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250386846-A1 Food Compositions Including Aragonite PLCG2, PLCG1, PLCB3 PDE4A 3601/4885ADORA2A 2335/4885PDE4B 3149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.